Stock DNA
Pharmaceuticals & Biotechnology
CNY 16,653 Million (Large Cap)
46.00
NA
1.05%
-0.32
16.07%
4.99
Revenue and Profits:
Net Sales:
666 Million
(Quarterly Results - Sep 2025)
Net Profit:
190 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.0%
0%
-6.0%
6 Months
-15.06%
0%
-15.06%
1 Year
33.8%
0%
33.8%
2 Years
49.74%
0%
49.74%
3 Years
28.87%
0%
28.87%
4 Years
-2.09%
0%
-2.09%
5 Years
-13.85%
0%
-13.85%
Double Medical Technology, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.93%
EBIT Growth (5y)
-3.02%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.53
Tax Ratio
10.39%
Dividend Payout Ratio
57.85%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.11%
ROE (avg)
13.80%
Valuation key factors
Factor
Value
P/E Ratio
46
Industry P/E
Price to Book Value
6.99
EV to EBIT
47.74
EV to EBITDA
31.14
EV to Capital Employed
9.21
EV to Sales
8.98
PEG Ratio
0.18
Dividend Yield
0.80%
ROCE (Latest)
19.28%
ROE (Latest)
15.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
665.80
660.10
0.86%
Operating Profit (PBDIT) excl Other Income
150.00
208.60
-28.09%
Interest
1.00
1.80
-44.44%
Exceptional Items
29.60
5.80
410.34%
Consolidate Net Profit
189.60
146.70
29.24%
Operating Profit Margin (Excl OI)
225.30%
223.90%
0.14%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 0.86% vs 19.95% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 29.24% vs 30.40% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,116.50
1,524.40
38.84%
Operating Profit (PBDIT) excl Other Income
545.80
202.20
169.93%
Interest
6.90
7.50
-8.00%
Exceptional Items
3.60
4.90
-26.53%
Consolidate Net Profit
385.30
86.30
346.47%
Operating Profit Margin (Excl OI)
152.90%
5.10%
14.78%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 38.84% vs 7.52% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 346.47% vs -21.26% in Dec 2023
About Double Medical Technology, Inc. 
Double Medical Technology, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






